Cash, cash equivalents and marketable securities were $279.1M as of December 31, 2022, compared with $375.1M in cash, cash equivalents, and marketable securities as of December 31, 2021. The company continues to believe that its cash position will fund its operating plan into 2025. "Generation Bio is aiming to be the new modality leader for non-viral DNA therapeutics. In the past year, we’ve made significant progress across our non-viral DNA therapeutics platform, most importantly in optimizing the biodistribution profile of our cell-targeted lipid nanoparticle (ctLNP) delivery system," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "We are currently engineering novel ctLNPs with two distinct biodistribution profiles that could each enable a broad pipeline of liver disease programs, as well as programs for other tissues and cell types. Our focus for 2023 is to achieve proof-of-concept for either of these ctLNP types, which could unlock tremendous value for our pipeline."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GBIO:
